Last reviewed · How we verify

Salvat — Portfolio Competitive Intelligence Brief

Salvat pipeline: 0 marketed, 0 filed, 5 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
G238 G238 phase 3
DF277 DF277 phase 3 SGLT2 inhibitor SGLT2 Diabetes
DF289 DF289 phase 3
DF289 plus DF277 DF289 plus DF277 phase 3
SVT-15652 SVT-15652 phase 3 sodium channel blocker cardiac sodium channel Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. AJU Pharm Co., Ltd. · 1 shared drug class
  3. Aciex Therapeutics, Inc. · 1 shared drug class
  4. Abbott · 1 shared drug class
  5. AceLink Therapeutics, Inc. · 1 shared drug class
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. AO GENERIUM · 1 shared drug class
  8. ADvantage Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Salvat:

Cite this brief

Drug Landscape (2026). Salvat — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/salvat. Accessed 2026-05-13.

Related